Abstract
Novel 4,4-disubstituted cyclohexylbenzamide inhibitors of 11beta-HSD1 were optimized to account for liabilities relating to in vitro pharmacokinetics, cytotoxicity and protein-related shifts in potency. A representative compound showing favorable in vivo pharmacokinetics was found to be an efficacious inhibitor of 11beta-HSD1 in a rat pharmacodynamic model (ED(50)=10mg/kg).
MeSH terms
-
11-beta-Hydroxysteroid Dehydrogenase Type 1 / antagonists & inhibitors*
-
11-beta-Hydroxysteroid Dehydrogenase Type 1 / metabolism
-
Animals
-
Benzamides / chemistry*
-
Benzamides / pharmacology
-
Dose-Response Relationship, Drug
-
HeLa Cells
-
Humans
-
Macaca fascicularis
-
Rats
-
Rats, Sprague-Dawley
-
Structure-Activity Relationship
Substances
-
Benzamides
-
11-beta-Hydroxysteroid Dehydrogenase Type 1